VYNE - Vyne stock jumps as VYN201 shows promise in mice model for lung disease

2023-04-19 08:51:50 ET

Vyne Therapeutics ( NASDAQ: VYNE ) stock rose ~10% premarket on Wednesday after the company said preclinical data showed positive effect of inhaled formulation of VYN201 in a mouse model of idiopathic pulmonary fibrosis (IPF).

IPF is a condition in which the lungs become scarred and breathing becomes difficult.

Lung fibrosis was induced in mice using a single intratracheal dose of bleomycin. Animals were divided in six treatment groups: untreated and unstimulated control, placebo, and one of four doses of VYN201 (0.1, 0.2, 0.5, and 1.0 mg/ml).

The company said VYN201 at 0.5 mg/ml and 1 mg/ml showed statistically significant reductions in Ashcroft scores (a measure of lung fibrosis) and levels of the tissue fibrosis biomarker, hydroxyproline, compared to the placebo group at day 21.

Mean control-adjusted lung fibrosis scores for VYN201 1 mg/ml were 65.8% lower compared to placebo group at day 21, the company added.

Meanwhile, at day 21, average blood oxygen saturation for the VYN201 1 mg/ml group was 92.4%, compared to 83.6% for the placebo group.

However, mean blood oxygen saturation for the untreated and unstimulated control group was 95.2%.

In addition, VYN201 1 mg/ml led to a 51.8% mean improvement in functional lung volume compared to animals receiving placebo therapy.

"The data from this well-validated preclinical model of IPF clearly demonstrates VYN201’s potential to deliver a potent anti-inflammatory and anti-fibrotic response," said Vyne's President and CEO David Domzalski.

The company noted that it has completed a phase 1a study of a topical formulation for VYN201 in healthy people and is now evaluating the topical formulation in a phase 1b trial in patients with non-segmental vitiligo.

According to Vyne VYN201 is a pan-bromodomain BET inhibitor intended to be locally-administered as a 'soft' drug for diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure.

VYNE +8.94% to $3.41 premarket April 19

For further details see: